Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

Name: Gene name corresponding to the UniProt ID
UniProt ID: UniProt accession number
Publication: Study Reference
Condition: e.g.ALS – Control, ALS Fast – ALS Slow
Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
Regulation: Direction of change (upregulated or downregulated)
Cohorts: Cohort size used for each study
Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au

Biomarker Name

UniProt ID

Condition

Publication

Sample Type

Sort by:

Ascending Descending

Total Records Found: 2896, showing 100 per page
Biomarker Name	UniProt ID	Publication	Condition	Sample Type	Regulation	Cohorts	Average age at onset	Average age at collection	Average PMI
PEA15	Q15121	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PEA15	Q15121	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDZRN4	Q6ZMN7	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
PDXP	Q96GD0	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PDXP	Q96GD0	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDXK	F2Z2Y4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDPK1;PDPK2	O15530	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
PDLIM5	Q96HC4	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
PDLIM5	Q96HC4	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
PDLIM1	O00151	Zubiri et al. 2018	ALS fast – ALS slow (late stage)	Plasma	Up	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
PDLIM1	O00151	Zubiri et al. 2018	Late ALS – Early ALS (ALS fast cohort)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
PDK2	D6RGV8	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDIA6	Q15084	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PDIA4	P13667	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDIA4	P13667	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
PDIA3	P30101	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
PDIA3	H7BZJ3	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDIA3	H7BZJ3	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
PDIA3	P30101	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Up	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
PDHB	P11177	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDHA1	P08559	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDGFB	P01127	Berrone et al. 2023	ALS – Control	Plasma	Up	16 ALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
PDGFA	P04085	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PDE5A	O76074	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
PDE2A	O00408	Berrone et al. 2023	fALS – Control	Plasma	Up	8 fALS, 8 control	62 ± 13 (sALS & fALS)	64 ± 11 (sALS & fALS)
PDCD6IP	Q8WUM4	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PDCD6IP	Q8WUM4	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PDCD6IP	Q8WUM4	Hayashi et al. 2020	ALS – Control	CSF exosome-enriched fractions	Up	3 ALS, 3 control		74.3
PDCD5	O14737	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
PCSK9	Q8NBP7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCSK2	P16519	Vu et al. 2023	ALS fast – ALS slow	CSF	Down	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
PCSK1N	Q9UHG2	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
PCSK1N	Q9UHG2	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PCSK1	P29120	Vu et al. 2023	ALS fast – ALS slow	CSF	Down	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
PCP4	P48539	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PCP4	P48539	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCOLCE	Q15113	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCMT1	P22061	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
PCMT1	P22061	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
PCMT1	H7BY58	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
PCMT1	P22061	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCMT1	P22061	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
PCLO	Q9Y6V0	Leoni et al. 2019	BO-ALS – LO-ALS	PBMCs	Down	12 BO-ALS, 12 LO-ALS	(39-76) (BO-ALS), (33-81) (LO-ALS)
PCDHB9	Q9Y5E1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCDH9	Q9HC56	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
PCDH19	Q8TAB3	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCDH18	Q9HCL0	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCDH10	Q9P2E7	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PCDH1	Q08174	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PCCB	P05166	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
PCBP3	P57721	Oeckl et al. 2020	ALS – Control	Spinal cord	Down	8 ALS, 7 control		59 (52-61)	36 (24-90)
PCBP1	Q15365	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
PCBP1	Q15365	Zubiri et al. 2018	Late ALS – Early ALS (ALS slow cohort)	Plasma	Down	8 ALS-fast, 6 ALS-slow	61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
PCBP1	Q15365	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PCBD2	H0YA52	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
PCBD1	P61457	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Up	8 ALS, 8 control	60	63.5	9.1
PC	P11498	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PBXIP1	Q96AQ6	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PARP1	P09874	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PARK7	Q99497	Filareti et al. 2017	Late ALS – Early ALS	PBMCs	Down	4 Early-ALS, 4 Late-ALS		50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
PARK7	Q99497	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PAPLN	O95428	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PAMR1	Q6UXH9	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
PALLD	Q8WX93	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
PALLD	Q8WX93	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
PAK1	Q13153	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PAICS	P22234	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
PAFAH1B1	P43034	Seyfried et al. 2018	ALS – Control	Prefrontal cortex	Down	8 ALS, 8 control	60	63.5	9.1
PADI2	Q9Y2J8	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PACSIN1	Q9BY11	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
PABPC1	A0A087WTT1	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
PAAF1	Q9BRP4	Andrés-Benito et al. 2020	ALS – Control	CSF	Down	15 ALS, 15 control		61 ± 10.8
PA2G4	Q9UQ80	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
P4HB	P07237	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
P4HB	P07237	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
P4HB	P07237	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Up	9 ALS, 8 control	57.6	62.8
OXCT1	P55809	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OTUD7A	Q8TE49	Collins et al. 2015	ALS – Control	CSF	Up	90 ALS, 80 control
OSMR	Q99650	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
OSCAR	Q8IYS5	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
ORM2	P19652	Vu et al. 2023	ALS fast – ALS slow	CSF	Up	6 ALS-fast, 5 ALS-slow	54.3 (ALS-fast), 43.4 (ALS-slow)	55.3 (ALS-fast), 52.2 (ALS-slow)
ORM1	P02763	Oeckl et al. 2020	ALS – Control	Spinal cord	Up	8 ALS, 7 control		59 (52-61)	36 (24-90)
ORM1	P02763	Xu et al. 2018	ALS – Control	Plasma	Up	42 ALS, 18 control		61.8 ± 9.6
ORM1	P02763	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OR51E2	Q9H255	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OPTN	Q96CV9	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
OPCML	Q14982	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OMG	P23515	Zhou et al. 2023	BO-ALS – Control	CSF	Up	4 BO-ALS, 5 SO-ALS, 5 control	63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS)	64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
OMG	P23515	Iridoy et al. 2019	ALS – Control	Spinal cord (AH)	Down	9 ALS, 8 control	57.6	62.8
OMG	P23515	Collins et al. 2015	ALS – Control	CSF	Down	90 ALS, 80 control
OMD	Q99983	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
OLR1	P78380	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
OLFL3	Q9NRN5	Andrés-Benito et al. 2020	ALS – Control	CSF	Up	15 ALS, 15 control		61 ± 10.8
OGN	P20774	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
OGDHL	Q9ULD0	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OGDH	Q02218	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Up	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)
OGDH	Q02218	Guise et al. 2023	ALS – Control	Spinal cord (SMNs)	Down	3 ALS, 3 control		69.3	9.2
OCIAD1	Q9NX40	Umoh et al. 2018	ALS – Control	Frontal cortex	Down	19 ALS, 10 control	55	59	10.6
OAF	Q86UD1	Barschke et al. 2020	C9-ALS – C9-Control	CSF	Down	16 C9-ALS, 11 asymptomatic C9-controls		60 (51-67)
NUDT4	Q9NZJ9	Leoni et al. 2019	BO-ALS – LO-ALS	Plasma	Down	14 BO-ALS, 16 LO-ALS	(45-85) (BO-ALS), (40-76) (LO-ALS)